CURRICULUM VITAE PERSONAL Name: Yong Sang Song, M.D., Ph.D. Current Rank: Professor, Department of Obstetrics and Gynecology College of Medicine Seoul National University Director, Cancer Research Institute Seoul National University Chairman, Graduate School of Cancer biology Seoul National University Director, Division of Gynecologic Oncology Cancer center, Seoul National University Hospital Office Address: 28 Yungun-Dong, Chongno-Ku Seoul 110-744, Korea TEL 82-2-2072-2822, 2387 FAX 82-2-762-3599 Home Address: Hyundai Apt. 22-904, Apgujeong-Dong, Kangnam-Ku , Seoul, Korea TEL 82-2-3444-3425, Citizenship: Korea Date and Place of Birth: August, 28, 1958 Seoul, Korea Tel: 82-2-2072-2922 FAX: 82-2-762-3599 CP: 010-9580-1023 E-mail: [email protected]
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
CURRICULUM VITAE
PERSONAL
Name: Yong Sang Song, M.D., Ph.D.
Current Rank:
Professor, Department of Obstetrics and Gynecology
College of Medicine
Seoul National University
Director, Cancer Research Institute
Seoul National University
Chairman, Graduate School of Cancer biology
Seoul National University
Director, Division of Gynecologic Oncology
Cancer center,
Seoul National University Hospital
Office Address: 28 Yungun-Dong, Chongno-Ku
Seoul 110-744, Korea
TEL 82-2-2072-2822, 2387
FAX 82-2-762-3599
Home Address: Hyundai Apt. 22-904,
Apgujeong-Dong, Kangnam-Ku , Seoul, Korea
TEL 82-2-3444-3425,
Citizenship: Korea
Date and Place of Birth: August, 28, 1958 Seoul, Korea
Tel: 82-2-2072-2922
FAX: 82-2-762-3599
CP: 010-9580-1023
E-mail: [email protected]
EDUCATION
Institution Degree and Dates Attended
College of Medicine M.D.
Seoul National University 1977 - 1983
Postgraduate School M.S.
Seoul National University 1985 - 1987
Postgraduate School Ph.D.
Seoul Natioanl University 1991 - 1994
INSTITUTIONAL TRAINING
Institution Position
Seoul National University Hospital Internship
1983 - 1984
Seoul National University Hospital Residency in Dep't. of Ob/Gyn
1984 - 1987
Seoul National University Hospital Fellowship in Dep't. of Ob/Gyn
1990 - 1993
University of Wyoming, Laramie, Research Fellow in Dep't. of Molecular Biology
Wyoming 1997 - 1999
ACADEMIC POSITION
Institution Rank
College of Medicine Instructor
Seoul National University Dep't. of Ob/Gyn
Seoul, Korea 1993 - 1995
College of Medicine Assistant Professor
Seoul National University Dep't. of Ob/Gyn
Seoul, Korea 1995 - 2000
College of Medicine Associate Professor
Seoul National University Dep't. of Ob/Gyn
Seoul, Korea 2001 - 2005
College of Medicine Professor
Seoul National University Dep't. of Ob/Gyn
Seoul, Korea 2006 – present
CEO, R&DB Foundation
Div. of Contract, Disbursement and Procurement
Associate Dean of Research Affairs
Seoul National University July 2006 – July 2008
Director,
Gynecologic oncology,
Cancer Center,
Seoul National University Hospital June 2009 - present
Director,
Cancer Research Institute,
Chairman,
Graduate School of Cancer biology
Seoul National University July 2009 – 2011 July
Affiliated professor
Guangdong medical college, China July 2010 -
CERTIFICAGTIONS AND LICENSES
National Board of Medical Doctors (No. 26,280) 1983
Korean Board of Obstetrics & Gynecology (no. 2083) 1987
SOCIETIES
Korean Cancer Society (KCA) : member (1991 - ) Editorial board member
Korean Medical Association(KMA) : member (1983 - )
Korean Society of Obstetrics and Gynecology(KSOG) : Member of Treasure
Committee (2001 - )
Korean Society of Colposcopy and Gynecologic Oncology :
Member of Scientific Committee (1999 - )
Secretary General (1995- 1997)
Chair of cancer prevention (since 2008 - )
Korean Society of Menopause(KSM) : Member (1999 - )
Korean Society of Gynecologic Endoscopy (KSGE) : Member (1999 - )
Korean Society of Ultrasound in Obstetrics and Gynecology (KSUOG)
Korean Society of Urogynecology :
Chairman, Scientific committee (Jun, 2006)
Member of Scientific Committee (2002 - )
Secretary General (2000 - 2002)
President elect (2012 - )
Korean Society of Psychosomatic Obstetrics and Gynecology(KSPOG) :
Member of Ethics Committee (2000 - )
Asian Clinical Oncology Society (ACOS) : Member of Scientific Committee, Local
Organizing Committee (2001 - 2003)
American Association of Cancer Research (AACR) : active member, 1987
International WHO'S WHO Historical Society™ : member, 2006 (Jan), 2007 (Jan)
Maquis WHO'S WHO Historical Society™ in the World, and in Health and
Medicine: member, (2009 - )
Who's Who in Science and Engineering (2011- 2012)
Asian Society of Gynecologic Oncology (ASGO) : Chair of Scientific Committee (Oct
2010 - )
International conference of NAPA :Organizer (2009 - )
President, Korean Society of Cancer Prevention (12/Nov 2012 - 2013)
AWARDS
1. First Prize Paper (Oct, 2002)
Korean Society of Obstetrics and Gynecology(KSOG)
2. The prize of scientific paper (Apr, 2004)
Korean Scientific Association
3. Grand prize (Oct, 2005)
Korean Society of Colposcopy and Gynecologic Oncology
4. Academic award (Jun 26- Jul 1 2006, Crete, Greece)
International conference on ovarian cancer
5. Professor of superiority in academy (Jul, 2008)
Seoul National University
6. Academy Award (Nov 18, 2010)
Clinical Research Institute, Seoul National University Hospital
MISCELLANEOUS
MILITARY DUTY : Lieutenant senior of Army, Republic of Korea
1987 - 1990
FAMILY STATUS : Married
Wife : Inhee Oh (44, May/30/1963)
Daughter : Eun Ji Song (18, March/20/1989)
Daughter : Yae Ji Song (10, October/10/1991)
Clinical Trials
1> CKD 602 – topoisomerase I inhibitor : Phase IIa and Phase IIb trial (2003- 2007)
1. Phase II evaluation of CKD-602, a camptothecin analog, administered on a
5-day schedule to patients with platinum-sensitive or -resistant ovarian
cancer. Lee HP, Seo SS, Ryu SY, Kim JH, Bang YJ, Park SY, Nam JH, Kang
SB, Lee KH, Song YS. Gynecol Oncol. 2008 Apr 9; [Epub ahead of print]
(Corresponding author)
2. Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin
in patients with recurrent epithelial ovarian cancer. Kim HS, Kang SB, Seo
SS, Han SS, Kim JW, Park NH, Kang SB, Lee HP, and Song YS. Ann N Y
Acad Sci. 2009 August;1171:627-634. (Corresponding author)
2> Gardasil – HPV vaccine : Phase III trial (2005 Oct – 2006 Aug)
Safety and immunogenicity of a vaccine targeting human papillomavirus
types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean
subjects. Kang S, Kim KH, Kim YT, Kim YT, Kim JH, Song YS, Shin SH,
Ryu HS, Han JW, Kang JH, Park SY. Int J Gynecol Cancer. 2007
3> Yondellis - ovarian cancer : Phase III (2005 Nov –2008)
4> Nonavalent vaccine (HPV): Phase II (2008 VI – now)
5> Cervarix (HPV vaccine) : Phase III (2007-2008)
6> Sorafenib (TKI; Bayer) : Phase III (2009 II – Now)
7> Farlesizumab (Folate receptor Ab: Morphotek) : Phase III (2009 – )
8> CKD 602- Phase IIb trial (2010 Nov- ) : PI for the project
9> Trinova (2012 ) : Sub PI for the project
Editorial board
1. Cancer letters since II since 2009
2. Cancer research and treatment since VI 2007
3. ISRN (International Scholarly Research Network (ISRN) series of journals of
Hindawi) Obstetrics and Gynecology since VI 2010
4. International journal of clinical medicine since June 2010
5. Advances in Molecular Imaging (AMI) since 27/Dec 2010
6. Journal of Traditional and Complementary Medicine (JTCM) since 27/Nov
2011
7. Open Journal of Oncology. Since March 2012
Reviewers of International Journal
1. Cancer letters
2. Gynecologic oncology
3. International journal of gynecologic cancer
4. British journal of cancer
5. BMC (Biomed Central) cancer
6. International journal of biologic science
7. Journal of pathology
8. Carcinogenesis
9. Cancer science
10. Cell biology international
11. Apoptosis
12. International journal of cancer
13. Molecular carcinogenesis
14. PLos One
15. Cancer research
MSD consultant
MSD : Consultant to Ovarian External Tumor-Specific Strategy committee (TSC) since
June 2010
MSD : Asian Pacific regional board member for HPV vaccine, since July 2007
GSK : HPV vaccine advisory board member, GSK from Jan 2008 Jan to Dec 2009
PUBLICATION
【 Book 】
1. Song YS, Lee CW, Ji I, Ji TH. Luteinizing Hormone. Encyclopedia of Molecular
Medicine, pp. 1962-5, Creighton TE. John Wiley & Sons, Inc. 2002
2. Song YS, Ryu KS, Yi JS, Ji I, Ji TH. Luteinizing hormone/choriogonadotropin
receptor. Encyclopedia of Molecular Medicine, pp. 1965, Creighton TE. John
Wiley & Sons, Inc. 2002
3. Song YS et al.(142) Textbook of family medicine (가정의학, 2001/5), 2001
4. Song YS et al. (60) Practice of geriatrics (임상노인의학, 2003/9), 2003
5. Song YS et al. Gynecologic oncology (부인 종양학, 1996/1), 1996
6. Song YS et al. Gynecology (부인과학, 1998/1), 1998
【 Papers 】
- Domestic journals : till 2009, 160 published
- International Journal 175. SERPINB3 in the Chicken Model of Ovarian Cancer: A Prognostic Factor for
Platinum Resistance and Survival in Patients with Epithelial Ovarian Cancer. Lim W, Kim HS, Jeong W, Ahn SE, Kim J, Kim YB, Kim MA, Kim MK, Chung HH, Song YS, Bazer FW, Han JY, Song G. PLoS One. 2012;7(11):e49869. doi: 10.1371/journal.pone.0049869. Epub 2012 Nov 21.
174. The influence of adjuvant radiotherapy on patterns of failure and survivals in
uterine carcinosarcoma. Park HJ, Kim HJ, Wu HG, Kim H, Ha SW, Kang SB, Song YS, Park NH, Kim JW. Radiat Oncol J. 2011 Dec;29(4):228-35. doi: 10.3857/roj.2011.29.4.228. Epub 2011 Dec 28.
173. Unfolded protein response to autophagy as a promising druggable target for
anticancer therapy. Suh DH, Kim MK, Kim HS, Chung HH, Song YS. Ann N Y Acad Sci. 2012 Oct;1271:20-32.
172. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA
cervical cancer: An international collaborative meta-analysis. Kim HS, Sardi JE, Katsumata N, Ryu HS, Nam JH, Chung HH, Park NH, Song YS, Behtash N, Kamura T, Cai HB, Kim JW. Eur J Surg Oncol. 2012 Oct 18. doi:pii: S0748-7983(12)01266-8. 10.1016/j.ejso.2012.09.003. [Epub ahead of print]
171. Loop Electrosurgical Excision Procedure Findings for Identification of Patients
With Early-Stage Cervical Cancer Suitable for Less Radical Surgery. Kim MK, Kim MA, Kim JW, Chung HH, Park NH, Song YS, Kang SB. Int J Gynecol Cancer. 2012 Jul 12. [Epub ahead of print]
170. Paradoxical expression of AHCYL1 affecting ovarian carcinogenesis between
chickens and women. Jeong W, Kim HS, Kim YB, Kim MA, Lim W, Kim J, Jang HJ, Suh DH, Kim K, Chung HH, Bazer FW, Song YS, Han JY, Song G. Exp Biol Med (Maywood). 2012 Jul 23.
169. Autophagy as a target for anticancer therapy and its modulation by phytochemicals.
Mi-Kyung Kim, Dong Hoon Suh, Jungyeob Seoung, Hee Seung Kim, Hyun Hoon Chung, and Yong-Sang Song. Journal of food and drug analysis Vol 20, suppl.1pp 241-245 April 2012
168. Genistein as a Potential Anticancer Agent against Ovarian Cancer. Jung-Yun Lee,
Hee Seung Kim, and Yong-Sang Song. Journal of Traditional and Complementary Medicine Vo1 1, No2, pp 96-104 June 2012
167. Predictive role of post-treatment [(18)F]FDG PET/CT in patients with uterine
cervical cancer. Hoon Chung H, Kim JW, Kang KW, Park NH, Song YS, Chung JK, Kang SB. Eur J Radiol. 2012 May 15
166. Pre-operative systemic inflammatory response markers in predicting lymph node
metastasis in endometrioid endometrial adenocarcinoma. Suh DH, Kim HS, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Eur J Obstet Gynecol Reprod Biol. 2012 Mar 23. [Epub ahead of print]
165. Systematic Lymphadenectomy for Survival in Patients with Endometrial Cancer: A
Meta-analysis. Kim HS, Suh DH, Kim MK, Chung HH, Park NH, Song YS. Jpn J Clin Oncol. 2012 Mar 6. [Epub ahead of print] (corresponding author)
164. Definitive radiotherapy for treatment of primary vaginal cancer: effectiveness and
prognostic factors. Jang WI, Wu HG, Ha SW, Kim HJ, Kang SB, Song YS, Park NH, Kim JW. Int J Gynecol Cancer. 2012 Mar;22(3):521-7.
163. Preoperative [F]FDG PET/CT predicts recurrence in patients with epithelial
ovarian cancer. Chung HH, Kwon HW, Kang KW, Kim JW, Park NH, Song YS, Kang SB. J Gynecol Oncol. 2012 Jan;23(1):28-34. Epub 2012 Jan 9.
162. Safe Criteria for Less Radical Trachelectomy in Patients with Early-Stage Cervical
Cancer: A Multicenter Clinicopathologic Study. Kim HS, Choi CH, Lim MC, Chang SJ, Kim YB, Kim MA, Kim TJ, Park SY, Kim BG, Song YS, Bae DS, Kim JW. Ann Surg Oncol. 2011 Dec 20. [Epub ahead of print]
161. Prognostic Value of Preoperative Metabolic Tumor Volume and Total Lesion
Glycolysis in Patients with Epithelial Ovarian Cancer. Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, Kang SB, Kim JW. Ann Surg Oncol. 2011 Nov 29.
160. An Occult Invasive Cervical Cancer Found After a Simple Hysterectomy: A 10-
Year Experience in a Single Institution. Suh DH, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Int J Gynecol Cancer. 2011 Nov 10. [Epub ahead of print]
159. 20year experience of postoperative radiotherapy in IB-IIA cervical cancer patients
with intermediate risk factors: Impact of treatment period and concurrent chemotherapy. Song S, Song C, Kim HJ, Wu HG, Kim JH, Park NH, Song YS, Kim JW, Kang SB, Ha SW. Gynecol Oncol. 2011 Oct 16.
158. Body mass index and survival in patients with epithelial ovarian cancer. Suh DH,
Kim HS, Chung HH, Kim JW, Park NH, Song YS, Kang SB. J Obstet Gynaecol Res. 2011 Aug 10.
157. Metabolic approaches to overcoming chemoresistance in ovarian cancer. Suh DH,
Kim MK, No JH, Chung HH, Song YS. (corresponding author) Ann N Y Acad Sci. 2011 Jul;1229(1):53-60
156. Seung Cheol Kim, Yong Sang Song, Young-Tae Kim, Young Tak Kim, Ki-Sung
Ryu, Bhavyashree Gunapalaiah, Dan Bi, Hans L Bock, Jong-Sup Park. Human
Papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: Immunogenicity and Safety in 15–25 year old healthy Korean women. J Gynecol Oncol. 2011;22(2):67-75.
155. Modulation of inflammatory signaling pathways by phytochemicals in ovarian
cancer. Kim MK, Kim K, Han JY, Lim JM, Song YS. Genes Nutr. 2011 May;6(2):109-15. Epub 2011 Feb 4. (corresponding author)
154. Human papillomavirus vaccine: Widening the scope for cancer prevention. No JH,
Kim MK, Jeon YT, Kim YB, Song YS. Mol Carcinog. 2011 Apr;50(4):244-53. doi: 10.1002/mc.20657. (corresponding author)
153. Underuse of ovarian transposition in reproductive-aged cancer patients treated by
primary or adjuvant pelvic irradiation. Han SS, Kim YH, Lee SH, Kim GJ, Kim HJ, Kim JW, Park NH, Song YS, Kang SB. J Obstet Gynaecol Res. 2011 Mar 31. doi: 10.1111/j.1447-0756.2010.01443.x. [Epub ahead of print]
152. Vaginal pH-Balanced Gel for the Control of Atrophic Vaginitis Among Breast
Cancer Survivors: A Randomized Controlled Trial. Lee YK, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Obstet Gynecol. 2011 Apr;117(4):922-7.
151. Cyclooxygenase-2 Is an Independent Predictor of Poor Prognosis in Uterine
Leiomyosarcomas. Lee CH, Roh JW, Choi JS, Kang S, Park IA, Chung HH, Jeon YT, Kim JW, Park NH, Kang SB, Song YS. Int J Gynecol Cancer. 2011 Mar 15. [Epub ahead of print] (corresponding author)
150. Postoperative nomogram predicting risk of recurrence after radical hysterectomy
for early-stage cervical cancer. Kim MK, Jo H, Kong HJ, Kim HC, Kim JW, Kim YM, Song YS, Kang SB, Mok JE, Lee HP. Int J Gynecol Cancer. 2010 Dec;20(9):1581-6.
149. Claudin 10 is a glandular epithelial marker in the chicken model as human
epithelial ovarian cancer. Seo HW, Rengaraj D, Choi JW, Ahn SE, Song YS, Song G, Han JY. Int J Gynecol Cancer. 2010 Dec;20(9):1465-73.
148. Significance of numbers of metastatic and removed lymph nodes in FIGO stage
IB1 to IIA cervical cancer: Primary surgical treatment versus neoadjuvant chemotherapy before surgery. Kim HS, Kim JH, Chung HH, Kim HJ, Kim YB, Kim JW, Park NH, Song YS, Kang SB. Gynecol Oncol. 2011 Feb 18. [Epub ahead of print]
147. Hypoxia-inducible factor 1α polymorphisms and early-stage cervical cancer. Kim
YH, Park IA, Park WY, Kim JW, Kim SC, Park NH, Song YS, Kang SB. Int J Gynecol Cancer. 2011 Jan;21(1):2-7.
146. Comparison of the efficacy of low anterior resection with primary anastomosis and
Hartmann's procedure in advanced primary or recurrent epithelial ovarian cancer.
Kim HS, Kim EN, Jeong SY, Chung HH, Kim YB, Kim JW, Park KJ, Park NH, Song YS, Park JG, Kang SB. Eur J Obstet Gynecol Reprod Biol. 2011 Jan 31. [Epub ahead of print]
145. Activation of mTOR signaling pathway associated with adverse prognostic factors
of epithelial ovarian cancer. No JH, Jeon YT, Park IA, Kim YB, Kim JW, Park NH, Kang SB, Han JY, Lim JM, Song YS. Gynecol Oncol. 2011 Jan 26. [Epub ahead of print] (Corresponding author)
144. Quantitative Detection of Serum Survivin and Its Relationship with Prognostic
Factors in Ovarian Cancer. No JH, Jeon YT, Kim YB, Song YS. Gynecol Obstet Invest. 2010 Dec 14. [Epub ahead of print]
143. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in
patients with cervical cancer. Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park NH, Song YS, Chung JK, Kang SB. Gynecol Oncol. 2010 Nov 23. [Epub ahead of print]
142. Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience
of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy. Lee JY, Kim YH, Kim MJ, Kim K, Chung HH, Park NH, Song YS, Kang SB. Arch Gynecol Obstet. 2010 Sep 28. [Epub ahead of print]
141. Post-treatment [(18)F]FDG maximum standardized uptake value as a prognostic
marker of recurrence in endometrial carcinoma. Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, Kang SB. Eur J Nucl Med Mol Imaging. 2010 Sep 14. [Epub ahead of print]
140. Identification of a patient group at low risk for parametrial invasion in early-stage
cervical cancer. Jung DC, Kim MK, Kang S, Seo SS, Cho JY, Park NH, Song YS, Park SY, Kang SB, Kim JW. Gynecol Oncol. 2010 Sep 3. [Epub ahead of print]
139. VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and
survival. Kim YH, Kim MA, Park IA, Park WY, Kim JW, Kim SC, Park NH, Song YS, Kang SB. Gynecol Oncol. 2010 Aug 24. [Epub ahead of print]
138. Matched-case comparison for the efficacy of neoadjuvant chemotherapy before
surgery in FIGO stage IB1-IIA cervical cancer. Kim HS, Kim JY, Park NH, Kim K, Chung HH, Kim YB, Kim JW, Kim HJ, Song YS, Kang SB. Gynecol Oncol. 2010 Aug 10. [Epub ahead of print]
136. Systematic lymphadenectomy for survival in epithelial ovarian cancer: a meta-
analysis. Kim HS, Ju W, Jee BC, Kim YB, Park NH, Song YS, Kim SC, Kang SB, Kim JW. Int J Gynecol Cancer. 2010 May;20(4):520-8.
135. Feasibility of less radical surgery for superficially invasive carcinoma of the cervix. Kim MK, Kim JW, Kim MA, Kim HS, Chung HH, Park NH, Park IA, Song YS, Kang SB. Gynecol Oncol. 2010 Jul 19. [Epub ahead of print]
134. Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer
treatment. Kim MK, Kim HS, Kim SH, Oh JM, Han JY, Lim JM, Juhnn YS, Song YS. Biochem Pharmacol. 2010 Jul 16. (corresponding author)
133. Wine drinking and epithelial ovarian cancer risk: a meta-analysis. Kim HS, Kim
JW, Shouten LJ, Larsson SC, Chung HH, Kim YB, Ju W, Park NH, Song YS, Kim SC, Kang SB. J Gynecol Oncol. 2010 Jun;21(2):112-8. Epub 2010 Jun 30
132. Comparison of the efficacy between paclitaxel/carboplatin and
doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience. Kim HS, Kim JW, Wu HG, Chung HH, Park NH, Song YS, Kang SB, Lee HP. J Obstet Gynaecol Res. 2010 Jun;36(3):598-604.
131. Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: A
case-matched comparison. Kim HS, Han KH, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Eur J Surg Oncol. 2010 Jun 5.
130. P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical
adenocarcinoma in Korean women. Roh JW, Kim BK, Lee CH, Kim J, Chung HH, Kim JW, Park NH, Song YS, Park SY, Kang SB. Oncol Res. 2010;18(9):453-9.
129. Role of magnetic resonance imaging and positron emission tomography/computed
tomography in preoperative lymph node detection of uterine cervical cancer. Chung HH, Kang KW, Cho JY, Kim JW, Park NH, Song YS, Kim SH, Chung JK, Kang SB. Am J Obstet Gynecol. 2010 Apr 30.
128. Preoperative [(18)F]FDG PET/CT maximum standardized uptake value predicts
recurrence of uterine cervical cancer. Chung HH, Nam BH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, Kang SB. Eur J Nucl Med Mol Imaging. 2010 Mar 30.
127. Comparison of the efficacy between topotecan- and belotecan-, a new
camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: A single institutional experience. Kim HS, Park NH, Kang S, Seo SS, Chung HH, Kim JW, Song YS, Kang SB. J Obstet Gynaecol Res. 2010 Feb;36(1):86-93.
126. Derepression of CLDN3 and CLDN4 during Ovarian Tumorigenesis Is Associated
with Loss of Repressive Histone Modifications. Kwon MJ, Kim SS, Choi YL, Jung HS, Balch C, Kim SH, Song YS, Marquez VE, Nephew KP, Shin YK. Carcinogenesis. 2010 Jan 6.
125. A hospital-based case-control study of identifying ovarian cancer using symptom index. Kim MK, Kim K, Kim SM, Kim JW, Park NH, Song YS, Kang SB. J Gynecol Oncol. 2009 Dec;20(4):238-42. Epub 2009 Dec 28.
124. Human papillomavirus type 16 E5 protein inhibits hydrogen peroxide-induced
apoptosis by stimulating ubiquitin/proteasome-mediated degradation of Bax in human cervical cancer cells. Oh JM, Kim SH, Cho EA, Song YS, Kim WH, Juhnn YS. Carcinogenesis. 2009 Dec 16. [Epub ahead of print]
123. Evaluation of preoperative criteria used to predict lymph node metastasis in
endometrial cancer. Han SS, Lee SH, Kim DH, Kim JW, Park NH, Kang SB, Song YS. Acta Obstet Gynecol Scand. 2009 Nov 17. (Corresponding author)
122. Prognostic significance of neutropenia during adjuvant concurrent
chemoradiotherapy in early cervical cancer. Kim YH, Chung HH, Kim JW, Park NH, Song YS, Kang SB. J Gynecol Oncol. 2009 Sep;20(3):146-50.
121. International Federation of Gynecology and Obstetrics (FIGO) staging system
revised: what should be considered critically for gynecologic cancer? Kim HS, Song YS. J Gynecol Oncol. 2009 Sep;20(3):135-6. (Corresponding author)
120. Expression of mTOR protein and its clinical significance in endometrial cancer.
No JH, Jeon YT, Park IA, Kang D, Kim JW, Park NH, Kang SB, Song YS. Med Sci Monit. 2009 Oct;15(10):BR301-305. (Corresponding author)
119. Effect of epidermal growh factor receptor inhibitor alone and in combination with
cisplatin on growth of vulvar cancer cells. Kim SH, Song YC, Kim SH, Jo H, and Song YS. Ann N Y Acad Sci. 2009 August ;1171: 642-648. (Corresponding author)
118. Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells
independently of cyclooxygenase. Kim SH, Kim SH, Song YC, and Song YS. Ann N Y Acad Sci. 2009 August;1171:635-641. (Corresponding author)
117. Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in
patients with recurrent epithelial ovarian cancer. Kim HS, Kang SB, Seo SS, Han SS, Kim JW, Park NH, Kang SB, Lee HP, and Song YS. Ann N Y Acad Sci. 2009 August;1171:627-634. (Corresponding author)
116. Genistein inhibits cell growth by modulating various Mitegen-Activatged Protein
Kinases and AKT in cervical cancer cells. Kim SH, Kim SH, Kim YB, Jeon YT, Lee SC, and Song YS. Ann N Y Acad Sci. 2009 August;1171:495-500. (Corresponding author)
115. Involvement of both extrinsic and intrinsic apoptotic pawhways in apoptosis
induced by genistein in human cervical cancer cells. Kim SH, Kim SH, Lee SC, and Song YS. Ann N Y Acad Sci. 2009 August;1171:196-201. (Corresponding author)
114. Cyclooxygenase-2 expression in cervical intraepithelial neoplasia. Kim K, Jeon YT,
Park IA, Kim JW, Park NH, Kang SB, and Song YS. Ann N Y Acad Sci. 2009 August;1171:111-115. (Corresponding author)
113. Expression of vascular endothelial rowth factor and hypoxia inducible factor-1a in
cervical neoplasia. No JH, Jo H, Kim S, Park IA, Kang D, Han SS, Kim JW, Park NH, Kang SB, Song YS. Ann N Y Acad Sci. 2009 August;1171:105-110. (Corresponding author)
112. Expression of MMP-2, MMP-9, and Urokinase-YType Plasminogen Activator in
Cervical Intraepithelial neoplasia. No JH, Jo J, Kim SH, Park IA, Kang D, Lee CH, Han SS, Kim JW, Park NH, Kang SB, Song YS. Ann N Y Acad Sci. 2009 August;1171:100-104. (Corresponding author)
111. Uterine corpus involvement as well as histologic type is an independent predictor
of ovarian metastasis in uterine cervical cancer. Kim MJ, Chung HH, Kim JW, Park NH, Song YS, Kang SB. J Gynecol Oncol. 2008 Sep;19(3):181-4. Epub 2008 Sep 30.
110. Inadvertent potential risk of neoadjuvant chemotherapy in cervical cancer. Kim K,
Kim MJ, Chung HH, Choi SC, Ryu SY, Kim JW, Park NH, Song YS, Kang SB. Med Hypotheses. 2009 Jun 22. [Epub ahead of print]
109. Rapid and high-throughput analysis of N-glycans from ovarian cancer serum using
96-well plate platform. Kim YG, Jeong HJ, Jang KS, Yang YH, Song YS, Chung J, Kim BG. Anal Biochem. 2009 May 17. [Epub ahead of print] PMID: 19457428 [PubMed - as supplied by publisher]
108. In vitro extreme drug resistance assay to taxanes or platinum compounds for the
prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study. Kim HS, Kim TJ, Chung HH, Kim JW, Kim BG, Park NH, Song YS, Bae DS, Kang SB. J Cancer Res Clin Oncol. 2009 May 16. [Epub ahead of print]
107. Clinical impact of under-diagnosis by frozen section examination is minimal in
borderline ovarian tumors. Kim K, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Eur J Surg Oncol. 2009 Mar 24. [Epub ahead of print]
106. Involvement of NF-{kappa}B and AP-1 in COX-2 upregulation by Human
Papillomavirus 16 E5 oncoprotein. Kim SH, Oh JM, No JH, Bang YJ, Juhnn YS, Song YS. Carcinogenesis. 2009 Mar 25. [Epub ahead of print] (Corresponding author)
105. Risk factors for recurrence of vaginal intraepithelial neoplasia in the vaginal vault
after laser vaporization. Kim HS, Park NH, Park IA, Park JH, Chung HH, Kim JW, Song YS, Kang SB. Lasers Surg Med. 2009 Mar 16;41(3):196-202.
104. Value of second pass in loop electrosurgical excisional procedure. Kim K, Kang SB, Chung HH, Lee TS, Kim JW, Park NH, Song YS. J Korean Med Sci. 2009 Feb;24(1):110-3. Epub 2009 Feb 28.
103. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer
patients treated with taxanes and platinum compounds: A Korean population-based study. Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Gynecol Oncol. 2009 Feb 7.
102. Disease confined within the ovary and smaller amount of ascites are good
prognostic factors for survival of patients with squamous cell carcinoma arising from mature cystic teratoma of the ovary: A case series in Korea and review of the published reports. Kim HS, Kim JW, Chung HH, Park NH, Song YS, Kang SB. J Obstet Gynaecol Res. 2009 Feb;35(1):99-105.
101. Value of pelvic examination and imaging modality for the evaluation of tumor size
in cervical cancer. Lee YK, Han SS, Kim JW, Park NH, Song YS, Kang SB. J Gynecol Oncol. 2008 Jun;19(2):108-12. Epub 2008 Jun 20.
100. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on
preoperative CT and MRI. Kim HS, Kim JW, Cho JY, Chung HH, Park NH, Song YS, Kim SH, Kang SB. Eur J Surg Oncol. 2009 Jan 27. [Epub ahead of print]
99. A randomized prospective trial of the postoperative quality of life between
laparoscopic uterine artery ligation and laparoscopy-assisted vaginal hysterectomy for the treatment of symptomatic uterine fibroids: clinical trial design. Kim HS, Kim JW, Kim MK, Chung HH, Lee TS, Jeon YT, Kim YB, Jeon HW, Yun YH, Park NH, Song YS, Kang SB. Trials. 2009 Jan 29;10(1):8. [Epub ahead of print]
98. Presence of HPV type 6 in dysplasia and carcinoma arising from recurrent
respiratory papillomatosis. Jeong WJ, Park SW, Shin M, Lee YJ, Jeon YK, Jung YH, Hun Hah J, Kwon TK, Song YS, Kim KH, Sung MW. Head Neck. 2008 Dec 15.
97. Gonadotropin-releasing Hormone Receptor Expression in Endometrial Cancer. Jeon
YT, Kim YB, Park SY, Kim JW, Park NH, Kang SB, Song YS. Int J Gynecol Pathol. 2009 Jan;28(1):19-22. (corresponding author)
96. Matched-Case Comparison for the Role of Surgery in FIGO Stage Ib1-IIa
Squamous Cell Carcinoma of Cervix and Suspicious Para-Aortic Lymph Node Metastasis. Kim HS, Park NH, Wu HG, Cho JY, Chung HH, Kim JW, Song YS, Kim SH, Kang SB. Ann Surg Oncol. 2008 Nov 1. [Epub ahead of print]
95. Cyclooxygenase-2 expression in ovarian germ cell malignancies. Kidong Kim,
Yong-Tark Jeon, Jae Weon Kim, Noh-Hyun Park, Soon-Beom Kang, Hyo-Pyo Lee, In-Ae Park, Heebal Kim, Jeong Mook Lim, Jae Yong Han, and Yong sang Song. J.
Clin. Biochem. Nutr. 2008 July 43-1 Suppl 168-171 (corresponding author) 94. Human papillomavirus infection and cervical cancer prevention in Japan and Korea.
Konno R, Shin HR, Kim YT, Song YS, Sasagawa T, Inoue M, Park JS. Vaccine. 2008 Aug 19;26 Suppl 12:M30-42.
93. Significance of preoperative serum CA-125 levels in the prediction of lymph node
metastasis in epithelial ovarian cancer. Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Acta Obstet Gynecol Scand. 2008 Oct 24:1-7. [Epub ahead of print]
92. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms
are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer. Kim K, Kang SB, Chung HH, Kim JW, Park NH, Song YS. Gynecol Oncol. 2008 Oct 11. [Epub ahead of print]
91. Human papillomavirus E5 protein induces expression of the EP4 subtype of
prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. Oh JM, Kim SH, Lee YI, Seo M, Kim SY, Song YS, Kim WH, Juhnn YS. Carcinogenesis. 2008 Oct 9. [Epub ahead of print]
90. Role of Integrated PET-CT in Pelvic Lymph Node Staging of Cervical Cancer
before Radical Hysterectomy. Chung HH, Park NH, Kim JW, Song YS, Chung JK, Kang SB. Gynecol Obstet Invest. 2008 Oct 9;67(1):61-66. [Epub ahead of print]
89. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful
prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer. Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Onkologie. 2008 Jun;31(6):315-20. Epub 2008 May 27
88. Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-
stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin? Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Jpn J Clin Oncol. 2008 May 27.
87. Comparison of chemoradiation with radiation as postoperative adjuvant therapy in
cervical cancer patients with intermediate-risk factors. Kim K, Kang SB, Chung HH, Kim JW, Park NH, Song YS. Eur J Surg Oncol. 2008 May 17. [Epub ahead of print]
86. Predictive value of individualized tumor response testing by ATP-based
chemotherapy response assay in ovarian cancer. Han SS, Choi SH, Lee YK, Kim JW, Park NH, Song YS, Lee HP, Kang SB. Cancer Invest. 2008 May;26(4):426-30.
85. Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day
schedule to patients with platinum-sensitive or -resistant ovarian cancer. Lee HP, Seo SS, Ryu SY, Kim JH, Bang YJ, Park SY, Nam JH, Kang SB, Lee KH, Song YS.
Gynecol Oncol. 2008 Apr 9; [Epub ahead of print] (Corresponding author) 84. Feasibility of routine lymphadenectomy in clinical stage-I endometrial cancer. Han
SS, Cho JY, Park IA, Park SK, Jeon YT, Kim JW, Park NH, Kang SB, Lee HP, Song YS. Med Sci Monit. 2008 Apr;14(4):CR183-189. (Corresponding author)
83. Interleukin-12 p40 gene (IL12B) polymorphisms and the risk of cervical caner in
Korean women. Han SS, Cho EY, Lee TS, Kim JW, Park NH, Song YS, Kim JG, Lee HP, Kang SB. Eur J Obstet Gynecol Reprod Biol. 2008 Mar 24
82. The clinical impact of [(18)F]FDG PET/CT for the management of recurrent
endometrial cancer: correlation with clinical and histological findings. Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, Kang SB. Eur J Nucl Med Mol Imaging. 2008 Jan 8
81. Association of cyclin D1 G870A polymorphism with uterine leiomyoma in women
whose body mass index values are above 25 kg/m2. Han SS, No JH, Jeon YT, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Hum Reprod. 2008 Jan 7;
80. Gamma-knife radiosurgery as an optimal treatment modality for brain metastases
from epithelial ovarian cancer. Lee YK, Park NH, Kim JW, Song YS, Kang SB, Lee HP. Gynecol Oncol. 2008 Jan 10
79. Hereditary nonpolyposis colorectal cancer in endometrial cancer patients. Yoon SN,
Ku JL, Shin YK, Kim KH, Choi JS, Jang EJ, Park HC, Kim DW, Kim MA, Kim WH, Lee TS, Kim JW, Park NH, Song YS, Kang SB, Lee HP, Jeong SY, Park JG. Int J Cancer. 2008 Mar 1;122(5):1077-81.
78. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11,
16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. Kang S, Kim KH, Kim YT, Kim YT, Kim JH, Song YS, Shin SH, Ryu HS, Han JW, Kang JH, Park SY. Int J Gynecol Cancer. 2007
77. Characteristics of recurrence in adult-type granulosa cell tumor. Lee YK, Park NH,
Kim JW, Song YS, Kang SB, Lee HP. Int J Gynecol Cancer. 2007 Sep 14; [Epub ahead of print]
76. Efficacy and outcome of anterior vaginal wall repair using polypropylene mesh
(Gynemesh). Jo H, Kim JW, Park NH, Kang SB, Lee HP, Song YS. J Obstet Gynaecol Res. 2007 Oct;33(5):700-4. (corresponding author)
75. Increasing trend in the incidence of cervical cancer among the elderly in Korea: A
population-based study from 1993 to 2002. Jo H, Jeon YT, Hwang SY, Shin HR, Song YS, Kang SB, Lee HP, Kim JW. Acta Oncol. 2007;46(6):852-8.
74. Influences of cyclooxygenase-1 and -2 expression on the radiosensitivities of human
cervical cancer cell lines. Jeon YT, Song YC, Kim SH, Wu HG, Kim IH, Park IA,
Kim JW, Park NH, Kang SB, Lee HP, Song YS. Cancer Lett. 2007 Jun 28; [Epub ahead of print] (corresponding author)
73. Hypermethylation of the COX-2 gene is a potential prognostic marker for cervical
cancer. Jo H, Kang S, Kim JW, Kang GH, Park NH, Song YS, Park SY, Kang SB, Lee HP. J Obstet Gynaecol Res. 2007 Jun;33(3):236-41.
72. Can Preoperative MRI Accurately Evaluate Nodal and Parametrial Invasion in Early
Stage Cervical Cancer? Chung HH, Kang SB, Cho JY, Kim JW, Park NH, Song YS, Kim SH, Lee HP. Jpn J Clin Oncol. 2007 Jun 7; [Epub ahead of print]
71. NF-kappaB as a potential molecular target for cancer therapy. Lee CH, Jeon YT,
Kim SH, Song YS. Biofactors. 2007;29(1):19-35. (Review article, corresponding author)
70. Matrix metalloproteinase-1 promoter polymorphism and epithelial ovarian cancer:
Does ethnicity matter? Ju W, Kim JW, Park NH, Song YS, Kim SC, Kang SB, Lee HP. J Obstet Gynaecol Res. 2007 Apr;33(2):155-60.
69. Increased cyclooxygenase-2 expression associated with inflammatory cellular
infiltration in elderly patients with vulvar cancer. Lee TS, Jeon YT, Kim JW, Won JK, Park NH, Park IA, Juhnn YS, Kang SB, Lee HP, Song YS. Ann N Y Acad Sci. 2007 Jan;1095:143-53. (Corresponding author)
68. Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase
gene polymorphism with risk of cervical cancer in korean population. Lee TS, Jeon YT, Kim JW, Park NH, Kang SB, Lee HP, Song YS. Ann N Y Acad Sci. 2007 Jan;1095:134-42. (Corresponding author)
67. Akt involvement in Paclitaxel chemoresistance of human ovarian cancer cells. Kim
SH, Juhnn YS, Song YS. Ann N Y Acad Sci. 2007 Jan;1095:82-9. (Corresponding author)
66. Aromatase expression was not detected by immunohistochemistry in endometrial
cancer. Jeon YT, Park SY, Kim YB, Kim JW, Park NH, Kang SB, Lee HP, Song YS. Ann N Y Acad Sci. 2007 Jan;1095:70-5. (Corresponding author)
65. Apoptotic Effect of Celecoxib Dependent Upon p53 Status in Human Ovarian
Cancer Cells. Song YC, Kim SH, Juhnn YS, Song YS. Ann N Y Acad Sci. 2007 Jan;1095:26-34. (Corresponding author)
64. DNA Hypomethylation of CAGE Promotors in Squamous Cell Carcinoma of
Uterine Cervix. Lee TS, Kim JW, Kang GH, Park NH, Song YS, Kang SB, Lee HP. Ann N Y Acad Sci. 2006 Dec;1091:218-24
63. Epidermal growth factor 61 A/G polymorphism and uterine cervical cancer. Kang S,
Kim JW, Park NH, Song YS, Park SY, Kang SB, Lee HP. Int J Gynecol Cancer.
2007 Feb 19; [Epub ahead of print] 62. The C19007T Polymorphism of ERCC1 and Its Correlation with the Risk of
Epithelial Ovarian and Endometrial Cancer in Korean Women. A Case Control Study. Jo H, Kang S, Kim SI, Kim JW, Park NH, Song YS, Park SY, Kang SB, Lee HP. Gynecol Obstet Invest. 2007 Feb 20;64(2):84-88 [Epub ahead of print]
61. Interleukin-1 Beta-511 polymorphism and risk of cervical cancer. Kang S, Kim JW,
Park NH, Song YS, Park SY, Kang SB, Lee HP. J Korean Med Sci. 2007 Feb;22(1):110-3.
60. Characterization of surgically transposed ovaries in integrated PET/CT scan in
patients with cervical cancer. Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, Kang SB, Lee HP. Acta Obstet Gynecol Scand. 2007;86(1):88-93.
59. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis
and prognosis in endometrial cancer. Chung HH, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Acta Obstet Gynecol Scand. 2006;85(12):1501-5.
58. Association of promoter hypermethylation of the RASSF1A gene with prognostic
parameters in endometrial cancer. Jo H, Kim JW, Kang GH, Park NH, Song YS, Kang SB, Lee HP. Oncol Res. 2006;16(4):205-9.
57. Accuracy of MR imaging for the prediction of myometrial invasion of endometrial
carcinoma. Chung HH, Kang SB, Cho JY, Kim JW, Park NH, Song YS, Kim SH, Lee HP. Gynecol Oncol. 2006 Nov 7; [Epub ahead of print]
56. Role of [(18)F]FDG PET/CT in the assessment of suspected recurrent ovarian
cancer: correlation with clinical or histological findings. Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, Kang SB, Lee HP. Eur J Nucl Med Mol Imaging. 2006 Nov 7; [Epub ahead of print]
55. Clinical impact of integrated PET/CT on the management of suspected cervical
cancer recurrence. Chung HH, Jo H, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, Kang SB, Lee HP. Gynecol Oncol. 2006 Oct 13; [Epub ahead of print]
54. Isolated full-thickness cervical stromal invasion warrants post-hysterectomy pelvic
radiotherapy in FIGO stages IB-IIA uterine cervical carcinoma. Moon SH, Wu HG, Ha SW, Lee HP, Kang SB, Song YS, Park NH, Kim JW, Park IA, Kim BH. Gynecol Oncol. 2006 Aug 24; [Epub ahead of print]
53. Feasibility of ovarian preservation in patients with early stage endometrial
carcinoma. Lee TS, Jung JY, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Gynecol Oncol. 2006 Aug 1; [Epub ahead of print]
52. XRCC1 R399Q polymorphism is associated with response to platinum-based
neoadjuvant chemotherapy in bulky cervical cancer. Chung HH, Kim MK, Kim JW,
Park NH, Song YS, Kang SB, Lee HP. Gynecol Oncol. 2006 Jul 26; [Epub ahead of print]
51. Cyclooxygenases in cancer : chemoprevention and sensitization to conventional
therapies. Jeon YT, Song YS. Mini Rev Med Chem. 2006 Jul;6(7):827-33. (Review; Corresponding author)
50. Association between excision repair cross-complementation group 1 polymorphism
and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Kang S, Ju W, Kim JW, Park NH, Song YS, Kim SC, Park SY, Kang SB, Lee HP. Exp Mol Med. 2006 Jun 30;38(3):320-4.
49. GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells. Kim SH,
Hwang CI, Juhnn YS, Lee JH, Park WY, Song YS. Carcinogenesis. 2007 Jan;28(1):223-31. (Corresponding author)
48. Patterns of failure after postoperative radiation therapy for endometrial carcinoma.
Kim S, Wu HG, Lee HP, Kang SB, Song YS, Park NH, Ha SW. Cancer Res Treat. 2006;38(3):133-8. Epub 2006 Jun 30.
47. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial
growth factor through the activation of epidermal growth factor receptor, MEK/ ERK1,2 and PI3K/Akt. Kim SH, Juhnn YS, Kang S, Park SW, Sung MW, Bang YJ, Song YS. Cell Mol Life Sci. 2006 Apr 5; [Epub ahead of print] (Corresponding author)
46. Good correlation of HPV DNA test between self-collected vaginal and clinician-
collected cervical samples by the oligonucleotide microarray. Seo SS, Song YS, Kim JW, Park NH, Kang SB, Lee HP. Gynecol Oncol. 2006 Jan 10; [Epub ahead of print] (Corresponding author)
45. Comparison of DNA hypermethylation patterns in different types of uterine cancer:
Cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Kang S, Kim JW, Kang GH, Lee S, Park NH, Song YS, Park SY, Kang SB, Lee HP. Int J Cancer. 2006 May 1;118(9):2168-71.
44. Aggressive work-up is needed for menopausal women with atypical glandular cells
of uncertain significance (AGUS) Pap smear. Lee DO, Jo HI, Chung YK, JW Kim, Park NH, Song YS, Kang SB, Lee HP. Cancer Therapy. 2005 Oct 21; 3 ; 435-442
43. Assessing clinical performance of gynecology residents: sonographic evaluation of
adnexal masses based on morphological scoring systems. Lee TS, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Ultrasound Obstet Gynecol. 2005 Dec;26(7):776-9.
42. Steroid receptor expressions in endometrial cancer: Clinical significance and
epidemiological implication. Jeon YT, Park IA, Kim YB, Kim JW, Park NH, Kang
SB, Lee HP, Song YS. Cancer Lett. 2005 Sep 13; [Epub ahead of print] (Corresponding author)
41. Elevation of cyclooxygenase-2 is related to lymph node metastasis in
adenocarcinoma of uterine cervix. Kang S, Kim MH, Park IA, Kim JW, Park NH, Kang D, Yoo KY, Kang SB, Lee HP, Song YS. Cancer Lett. 2005 Aug 16; [Epub ahead of print] (Corresponding author)
40. Sequence variation and the transcriptional activity of the upstream regulatory region
in human papillomavirus 16 E7 variants in cervical cancer of Korean women. Kim YB, Song YS, Jeon YT, Park JS, Um SJ, Kim JW, Park NH, Kang SB, Lee HP. Oncol Rep. 2005 Aug;14(2):459-64. (Corresponding author)
39. Cyclin D1 polymorphism and the risk of endometrial cancer. Kang S, Kim JW, Park
NH, Song YS, Kang SB, Lee HP. Gynecol Oncol. 2005 May;97(2):431-5. 38. Epstein-Barr virus plays little role in cervical carcinogenesis in Korean women. Seo
SS, Kim WH, Song YS, Kim SH, Kim JW, Park NH, Kang SB, Lee HP. Int J Gynecol Cancer. 2005 Mar-Apr;15(2):312-8. (Corresponding author)
37. Cyclin D1 G870A polymorphism and squamous cell carcinoma of the uterine cervix
in Korean women. Jeon YT, Kim JW, Song JH, Park NH, Song YS, Kang SB, Lee HP. Cancer Lett. 2005 Jun 8;223(2):259-63.
36. DNA repair gene XRCC1 Arg399Gln polymorphism is associated with increased
risk of uterine leiomyoma. Jeon YT, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Hum Reprod. 2005 Mar 10; [Epub ahead of print]
35. Feasibility of Radical Surgery in the Management of Elderly Patients with Uterine
Cervical Cancer in Korea. Choi YS, Kim YH, Kang S, Jeon YT, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Gynecol Obstet Invest. 2005 Jan 28;59(3):165-170 [Epub ahead of print]
34. Polymorphism in the E6 gene of human papillomavirus type 16 in the cervical
tissues of Korean women. Kang S, Jeon YT, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Int J Gynecol Cancer. 2005 Jan-Feb;15(1):107-12. (Corresponding author)
33. Promoter polymorphism in the matrix metalloproteinase-1 and risk of cervical
cancer in Korean women. Ju W, Kang S, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Cancer Lett. 2005 Jan 20;217(2):191-196.
32. Polymorphism in the nuclear factor kappa-B binding promoter region of
cyclooxygenase-2 is associated with an increased risk of bladder cancer. Kang S, Kim YB, Kim MH, Yoon KS, Kim JW, Park NH, Song YS, Kang D, Yoo KY, Kang SB, Lee HP. Cancer Lett. 2005 Jan 10;217(1):11-6 (Corresponding author)
31. Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG
island hypermethylation in uterine cervical cancer. Kang S, Kim JW, Kang GH, Park NH, Song YS, Kang SB, Lee HP. Gynecol Oncol. 2005 Jan;96(1):173-80
30. Cyclooxygenase-2 and p53 expressions in endometrial cancer. Jeon YT, Kang S,
Kang DH, Yoo KY, Park IA, Bang YJ, Kim JW, Park NH, Kang SB, Lee HP, Song YS. Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1538-42. (Corresponding author)
29. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase
using NF-kappaB as a possible target. Kim SH, Song SH, Kim SG, Chun KS, Lim SY, Na HK, Kim JW, Surh YJ, Bang YJ, Song YS. J Cancer Res Clin Oncol. 2004 Sep;130(9):551-60. (Corresponding author)
28. Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of
AP-1 and p38 MAP kinase in mouse skin. Chun KS, Kim SH, Song YS, Surh YJ. Carcinogenesis. 2004 May;25(5):713-22. Epub 2004 Jan 16.
27. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Roh
JW, Kim JW, Park NH, Song YS, Park IA, Park SY, Kang SB, Lee HP. Gynecol Oncol. 2004 May;93(2):499-505.
26. Genetic polymorphisms of GSTM1, p21, p53 and HPV infection with cervical
cancer in Korean women. Lee SA, Kim JW, Roh JW, Choi JY, Lee KM, Yoo KY, Song YS, Kang D. Gynecol Oncol. 2004 Apr;93(1):14-8.
25. Expression of cyclooxygenase-2 in association with clinicopathological prognostic
factors and molecular markers in epithelial ovarian cancer. Seo SS, Song YS, Kang DH, Park IA, Bang YJ, Kang SB, Lee HP. Gynecol Oncol. 2004 Mar;92(3):927-35. (Corresponding author)
24. The natural history of hydronephrosis after radical hysterectomy with no
intraoperatively recognisable injury to the ureter: a prospective study. Paick SH, Oh SJ, Song YS, Kim HH. BJU Int. 2003 Nov;92(7):748-50.
23. Multiple HPV infection in cervical cancer screened by HPVDNAChip. Lee SA,
Kang D, Seo SS, Jeong JK, Yoo KY, Jeon YT, Kim JW, Park NH, Kang SB, Lee HP, Song YS. Cancer Lett. 2003 Aug 20;198(2):187-92. (Corresponding author)
22. Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse
skin through suppression of extracellular signal-regulated kinase activity and NF-{kappa}B activation. Chun KS, Keum YS, Han SS, Song YS, Kim SH, Surh YJ. Carcinogenesis. 2003 Sep;24(9):1515-24. Epub 2003 Jul 04. [Epub ahead of print].
21. Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in
primary cervical cancer and at metastatic lymph nodes. Kim MH, Seo SS, Song YS,
Kang DH, Park IA, Kang SB, Lee HP. Gynecol Oncol. 2003 Jul;90(1):83-90. (Corresponding author)
20. Functional screening of genes suppressing TRAIL-induced apoptosis: distinct
inhibitory activities of Bcl-XL and Bcl-2. Kim IK, Jung YK, Noh DY, Song YS, Choi CH, Oh BH, Masuda ES, Jung YK. Br J Cancer. 2003 Mar 24;88(6):910-7.
19. Interferon, alpha 17(IFNA17) Ile 184 Arg polymorphism and cervical cancer risk.
Jae Weon Kim, Ju Won Roh, Noh Hyun Park, Yong Sang Song, Soon Beom Kang, Hyo Pyo Lee. Cancer Letters 2003;189:183-188
18. Common and differential mechanisms of gonadotropin receptors. Yi CS, Song YS,
Ryu KS, Sohn J, Ji I, Ji TH. Cell Mol Life Sci 59, 932 2002 17. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women.
Roh JW, Kim MH, Seo SS, Kim SH, Kim JW, Park NH, Song YS, Park SY, Kang SB, Lee HP. Cancer Lett 2002;184(1):57-63.
16. Cis- and trans-activation of hormone receptors: the LH Receptor. Ji I, Lee C, Song
Y, Conn PM, Ji TH. Mol Endocrinol 2002 Jun;16(6):1299-308. 15. Two defective heterozygous luteinizing hormone receptors can rescue hormone
action. Lee C, Ji I, Ryu K, Song Y, Conn PM, Ji TH. J Biol Chem 2002 May 3;277(18): 15795-800.
14. Polymorphism in codon 31 of p21 and cervical cancer susceptibility. Roh JW, Kim
MH, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Cancer Lett 2001;165(1):59-62.
13. Polymorphism of TP53 codon 72 and the risk of cervical cancer among Korean
women. Kim JW, Roh JW, Park NH, Song YS, Kang SB, Lee HP. Am J Obstet Gynecol 2001;184(2):55-58.
12. A comparison of the therapeutic efficacy of large loop excision of the
transformation zone and hysterectomy for the treatment of cervical intraepithelial neoplasia III. Kang SB, Roh JW, Kim JW, Park NH, Song YS, Lee HP. Int J Gynecol Cancer 2001;11:387-391.
11. Hormone interactions to Leu-rich repeats in the gonadotropin receptors. I. Analysis
of Leu-rich repeats of human luteinizing hormone/ chorionic gonadotropin receptor and follicle-stimulating hormone receptor. Song YS, Ji I, Beauchamp J, Isaacs NW, Ji TH. J Biol Chem 2001;276(5):3426-3435.
10. Hormone interactions to Leu-rich repeats in the gonadotropin receptors. II. Analysis
of Leu-rich repeat 4 of human luteinizing hormone/ chorionic gonadotropin
Related Documents
